A recent study of Lee et al. tested the efficacy of the addition of the same dose of simvastatin (i.e., 80 mg once daily) to cetuximab and irinotecan in KRAS mutant CRC patients failing prior oxaliplatin, fluoropyrimidine and irinotecan based therapy [27]. Here, KRAS is linked to colorectal carcinoma.